Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_81ba2c4156354c844d4a8883be561f00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-775 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-775 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C09H1-04 |
filingDate |
2013-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2017-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_64432d3f591ec4d10e8fd0bb7d1f969d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b2e02f736c1f1e9e6ccdfc758cabb4b9 |
publicationDate |
2017-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-9730980-B2 |
titleOfInvention |
Method of treating type I diabetes using apolipoprotein A-IV |
abstract |
Methods for treating type one diabetes mellitus in a subject in need thereof and pharmaceutical compositions for the treatment of type one diabetes mellitus are disclosed, including combination therapies with insulin. The methods include administering an effective amount of apolipoprotein A-IV to the subject having type I diabetes. The pharmaceutical composition includes apolipoprotein A-IV formulated for administration to a subject for the treatment of type one diabetes mellitus. |
priorityDate |
2012-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |